About AVT
Browse Articles
Customer Services

Original article

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection

Joseph J Eron, David A Cooper, Roy T Steigbigel, Bonaventura Clotet, Patrick Yeni, Kim M Strohmaier, Anthony J Rodgers, Richard J Barnard, Bach-Yen T Nguyen, Hedy Teppler, the BENCHMRK Study Teams

Corresponding author name: Hedy Teppler
Corresponding author e-mail: hedy_teppler@merck.com

Citation: Antiviral Therapy 2015; 20:307-315
doi: 10.3851/IMP2912

Date accepted: 01 October 2014
Date published online: 27 October 2014


Background: We explored the relationship between virological response in the first year of treatment and long-term outcomes in the BENCHMRK studies.

Methods: Patients failing antiretroviral treatment with 3-class resistant HIV-1 received double-blinded raltegravir (or placebo) with optimized background therapy (OBT) until week 156, followed by open-label raltegravir with OBT up to week 240. In this exploratory analysis of patients randomized to raltegravir, virological response over weeks 16–48 was categorized as continuous suppression (CS; viral RNA [vRNA] always <50 copies/ml), low-level viraemia (LLV; vRNA always <400 copies/ml, >50 copies/ml at least once), or not suppressed (NS; vRNA >400 copies/ml at least once). The association between these first-year vRNA response categories and baseline factors was analysed with univariate and multivariate models. Virological and immunological outcomes for years 2–5 were assessed by first-year vRNA response category (observed failure approach).

Results: Baseline vRNA, baseline CD4+ T-cell count and rapid viral decay (vRNA <50 copies/ml between weeks 2–12) correlated with first-year vRNA response (P<0.001); only rapid viral decay remained significant by multiple regression. Virological response rates were similar in the LLV and CS groups and lowest in the NS group. CD4+ T-cell count increased through week 240 in the CS and LLV groups. Time to loss of virological response (confirmed vRNA ≥400 copies/ml) through week 240 did not support as strong a difference between the LLV and CS groups (log-rank P=0.11) as previously reported through weeks 156 and 192 (P<0.05).

Conclusions: Treatment-experienced patients on a raltegravir-based regimen with early LLV may have long-term virological and immunological benefit when their therapy is maintained.


Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.